Phase II Study of Vinflunine in Malignant Pleural Mesothelioma | Zendy

Denis Talbot | Zendy; J. Margery | Zendy; G Dabouis | Zendy; G. Dark | Zendy; Henry Taylor | Zendy; Hélène Boussemart | Zendy; V. Cadic | Zendy; MarieClaire Pinel | Zendy; Alain Rivière | Zendy; Liliane Ollivier | Zendy; Pierre Ruffiè | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Phase II Study of Vinflunine in Malignant Pleural Mesothelioma

Author(s) -

Denis Talbot,

J. Margery,

G Dabouis,

G. Dark,

Henry Taylor,

Hélène Boussemart,

V. Cadic,

MarieClaire Pinel,

Alain Rivière,

Liliane Ollivier,

Pierre Ruffiè

Publication year - 2007

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2007.12.5641

Subject(s) - medicine , neutropenia , response evaluation criteria in solid tumors , mesothelioma , nausea , adverse effect , surgery , anemia , lung cancer , febrile neutropenia , phases of clinical research , chemotherapy , gastroenterology , pathology

Malignant pleural mesothelioma (MPM) is a disease of increasing incidence for which treatment options are limited. This study reports the clinical efficacy data for vinflunine, a novel microtubule inhibitor, in MPM.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research